Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice

16 Aug 2023

Abstract excerpt

Pretomanid (PA-824), a novel anti-tuberculosis (TB) nitroimidazoxazine, has been approved for multi-drug-resistant TB treatment for a few years. Pretomanid has been demonstrated to be highly active against Mycobacterium tuberculosis when combined with other anti-TB drugs. This review provides an update of the current knowledge on the modes of action, resistance mechanisms, emergence of drug resistance, and status...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37595848
DOI: 10.1016/j.ijantimicag.2023.106953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practicePMID 37595848Read ↗

Delamanid Resistance: Update and Clinical ManagementSemantic proximity Read ↗

Widespread loss-of-function mutations implicating preexisting resistance to new or repurposed anti-tuberculosis drugsSemantic proximity Read ↗

Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis.Semantic proximity Read ↗

Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.Semantic proximity Read ↗

Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Semantic proximity Read ↗

Bedaquiline Resistance: Its Emergence, Mechanism, and PreventionSemantic proximity Read ↗

Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysisSemantic proximity Read ↗

Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice?Semantic proximity Read ↗

Drug-Resistant Tuberculosis 2020: Where We StandSemantic proximity Read ↗

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.Semantic proximity Read ↗

Intracellular Drug Targets In Mycobacterium Tuberculosis Revealed By A Chemo-Genetic ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.